etrumadenantzimberelimabdomvanalimabNSCLCWashington Universitymetastatic non-small cell lung cancer
…relimab 360mg IV q3 weeks, domvanalimab 15mg/kg IV q3 weeks and etrumadenant 150mg PO daily. The primary endpoint was objective response rat…
2articles mentioning drugs
4drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: domvanalimab ×
domvanalimab
This drug is selected. Its supporting articles are shown below.
Articles mentioning domvanalimab
2 articles · page 1 of 1TIGIT inhibitorsEtigilimabRilvegostomigTIGIT inhibitorPD1 inhibitorDargistotugBAT6021tiragolumab
…clinical trials of TIGIT inhibitors should be questioned. Seven TIGIT inhibitors (all Fc-enabled) did not recapitulate in clinical trials the pr…